Nationwide Fund Advisors raised its holdings in Stemline Therapeutics, Inc. (NASDAQ:STML) by 7.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,755 shares of the biopharmaceutical company’s stock after acquiring an additional 855 shares during the period. Nationwide Fund Advisors owned about 0.05% of Stemline Therapeutics worth $117,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Wells Fargo & Company MN grew its position in Stemline Therapeutics by 3.8% in the first quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 500 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Stemline Therapeutics in the second quarter valued at about $147,000. Alliancebernstein L.P. bought a new position in Stemline Therapeutics in the second quarter valued at about $178,000. UBS Group AG grew its position in Stemline Therapeutics by 130.0% in the first quarter. UBS Group AG now owns 26,945 shares of the biopharmaceutical company’s stock valued at $230,000 after acquiring an additional 15,232 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Stemline Therapeutics by 18.5% in the second quarter. Rhumbline Advisers now owns 27,358 shares of the biopharmaceutical company’s stock valued at $252,000 after acquiring an additional 4,280 shares during the last quarter. Hedge funds and other institutional investors own 46.54% of the company’s stock.

Shares of Stemline Therapeutics, Inc. (STML) opened at $14.25 on Tuesday. Stemline Therapeutics, Inc. has a 12 month low of $5.50 and a 12 month high of $14.85.

A number of research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Stemline Therapeutics in a research report on Friday, November 10th. Cowen and Company reissued a “buy” rating on shares of Stemline Therapeutics in a research note on Tuesday, October 31st. Finally, ValuEngine lowered Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $33.40.

COPYRIGHT VIOLATION NOTICE: “Stemline Therapeutics, Inc. (STML) Holdings Lifted by Nationwide Fund Advisors” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/21/stemline-therapeutics-inc-stml-holdings-lifted-by-nationwide-fund-advisors.html.

Stemline Therapeutics Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.